Charmacy Pharmaceutical Co., Ltd.

SEHK:2289 Stock Report

Market Cap: HK$1.0b

Charmacy Pharmaceutical Management

Management criteria checks 4/4

Charmacy Pharmaceutical's CEO is Chuanglong Yao, appointed in Mar 2000, has a tenure of 24.67 years. total yearly compensation is CN¥728.07K, comprised of 87.4% salary and 12.6% bonuses, including company stock and options. directly owns 31.97% of the company’s shares, worth HK$319.75M. The average tenure of the management team and the board of directors is 2.6 years and 5.7 years respectively.

Key information

Chuanglong Yao

Chief executive officer

CN¥728.1k

Total compensation

CEO salary percentage87.4%
CEO tenure24.7yrs
CEO ownership32.0%
Management average tenure2.6yrs
Board average tenure5.7yrs

Recent management updates

There Could Be A Chance Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) CEO Will Have Their Compensation Increased

May 13
There Could Be A Chance Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) CEO Will Have Their Compensation Increased

Recent updates

There Could Be A Chance Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) CEO Will Have Their Compensation Increased

May 13
There Could Be A Chance Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) CEO Will Have Their Compensation Increased

There's Reason For Concern Over Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) Massive 40% Price Jump

Apr 24
There's Reason For Concern Over Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) Massive 40% Price Jump

Charmacy Pharmaceutical Co., Ltd. (HKG:2289) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Jan 19
Charmacy Pharmaceutical Co., Ltd. (HKG:2289) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

These 4 Measures Indicate That Charmacy Pharmaceutical (HKG:2289) Is Using Debt Reasonably Well

Oct 25
These 4 Measures Indicate That Charmacy Pharmaceutical (HKG:2289) Is Using Debt Reasonably Well

If EPS Growth Is Important To You, Charmacy Pharmaceutical (HKG:2289) Presents An Opportunity

Sep 17
If EPS Growth Is Important To You, Charmacy Pharmaceutical (HKG:2289) Presents An Opportunity

Is Charmacy Pharmaceutical (HKG:2289) A Risky Investment?

May 02
Is Charmacy Pharmaceutical (HKG:2289) A Risky Investment?

What Type Of Returns Would Charmacy Pharmaceutical's(HKG:2289) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Mar 15
What Type Of Returns Would Charmacy Pharmaceutical's(HKG:2289) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Are Dividend Investors Making A Mistake With Charmacy Pharmaceutical Co., Ltd. (HKG:2289)?

Feb 17
Are Dividend Investors Making A Mistake With Charmacy Pharmaceutical Co., Ltd. (HKG:2289)?

We Wouldn't Rely On Charmacy Pharmaceutical's (HKG:2289) Statutory Earnings As A Guide

Jan 27
We Wouldn't Rely On Charmacy Pharmaceutical's (HKG:2289) Statutory Earnings As A Guide

Returns On Capital At Charmacy Pharmaceutical (HKG:2289) Paint An Interesting Picture

Jan 09
Returns On Capital At Charmacy Pharmaceutical (HKG:2289) Paint An Interesting Picture

What Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) ROE Can Tell Us

Dec 22
What Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) ROE Can Tell Us

Reflecting on Charmacy Pharmaceutical's (HKG:2289) Share Price Returns Over The Last Three Years

Nov 29
Reflecting on Charmacy Pharmaceutical's (HKG:2289) Share Price Returns Over The Last Three Years

CEO Compensation Analysis

How has Chuanglong Yao's remuneration changed compared to Charmacy Pharmaceutical's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

CN¥52m

Mar 31 2024n/an/a

CN¥52m

Dec 31 2023CN¥728kCN¥636k

CN¥51m

Sep 30 2023n/an/a

CN¥74m

Jun 30 2023n/an/a

CN¥96m

Mar 31 2023n/an/a

CN¥93m

Dec 31 2022CN¥732kCN¥638k

CN¥90m

Sep 30 2022n/an/a

CN¥54m

Jun 30 2022n/an/a

CN¥18m

Mar 31 2022n/an/a

CN¥20m

Dec 31 2021CN¥679kCN¥646k

CN¥23m

Sep 30 2021n/an/a

CN¥29m

Jun 30 2021n/an/a

CN¥36m

Mar 31 2021n/an/a

CN¥38m

Dec 31 2020CN¥685kCN¥649k

CN¥41m

Sep 30 2020n/an/a

CN¥35m

Jun 30 2020n/an/a

CN¥29m

Mar 31 2020n/an/a

CN¥34m

Dec 31 2019CN¥714kCN¥650k

CN¥40m

Sep 30 2019n/an/a

CN¥41m

Jun 30 2019n/an/a

CN¥42m

Mar 31 2019n/an/a

CN¥44m

Dec 31 2018CN¥715kCN¥649k

CN¥45m

Sep 30 2018n/an/a

CN¥46m

Jun 30 2018n/an/a

CN¥47m

Mar 31 2018n/an/a

CN¥46m

Dec 31 2017CN¥713kCN¥650k

CN¥45m

Compensation vs Market: Chuanglong's total compensation ($USD100.54K) is below average for companies of similar size in the Hong Kong market ($USD233.02K).

Compensation vs Earnings: Chuanglong's compensation has been consistent with company performance over the past year.

CEO

Chuanglong Yao (54 yo)

24.7yrs

Tenure

CN¥728,071

Compensation

Mr. Chuanglong Yao has been Chief Executive Officer at Charmacy Pharmaceutical Co., Ltd. since March 2000 and serves as its Vice Chairman since May 31, 2023 and served as its Chairman since May 2015. Mr. Y...

Leadership Team

NamePositionTenureCompensationOwnership
Chuanglong Yao
CEO & Vice Chairman24.7yrsCN¥728.07k31.97%
HK$ 319.7m
Hanzi Zhang
CFO & Executive Director2.6yrsCN¥385.49kno data
Yuyan Zheng
VP & Executive Director9.3yrsCN¥991.13kno data
Zhijie Lin
Chief Logistics Officer & CTOno dataCN¥188.00kno data
Wai Ling Wong
Joint Company Secretary2.6yrsno datano data
Jiexi Yao
Joint Company Secretary2.6yrsno datano data

2.6yrs

Average Tenure

45yo

Average Age

Experienced Management: 2289's management team is considered experienced (2.6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Chuanglong Yao
CEO & Vice Chairman24.7yrsCN¥728.07k31.97%
HK$ 319.7m
Hanzi Zhang
CFO & Executive Director2.3yrsCN¥385.49kno data
Yuyan Zheng
VP & Executive Director9.5yrsCN¥991.13kno data
Chi Wai Wan
Independent Non-Executive Director8.9yrsCN¥144.00kno data
Jian Guan
Independent Non-Executive Director8.9yrsCN¥50.00kno data
Ling Zhang
Independent Supervisor9.5yrsno datano data
Xiyue Zheng
Employee Representative Supervisor9.5yrsno datano data
Hanguo Li
Independent Non-Executive Director1.5yrsCN¥29.30kno data
Zheng Fu
Non-Executive Director2.3yrsno datano data
Jingbin Yan
Non-Executive Chairman2.4yrsno datano data
Fei Xu
Non-Executive Director1.5yrsno datano data
Minghong Zhu
Chairman of the Board of Supervisors1.5yrsno datano data

5.7yrs

Average Tenure

49yo

Average Age

Experienced Board: 2289's board of directors are considered experienced (5.7 years average tenure).